Literature DB >> 8241346

Idarubicin is active on MDR cells: evaluation of DNA synthesis inhibition on P388 cell lines.

M Petrini1, L Mattii, P Valentini, A R Sabbatini, B Grassi, M Grandi.   

Abstract

Multidrug resistance is frequently found in patients affected by hematological malignancies and has been related to a poor prognosis of acute leukemia. In the present paper we report results concerning the activity of idarubicin, an anthracycline derivative, on the leukemic P388 and P388 doxorubicin-resistant cell lines. The results clearly show that idarubicin inhibits DNA synthesis in the resistant cell line more actively than doxorubicin.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8241346     DOI： 10.1007/bf01715052

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  21 in total

1.  Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.

Authors:  E Berman; M McBride
Journal:  Blood       Date:  1992-06-15       Impact factor: 22.113

2.  Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

Authors:  B Schott; J Robert
Journal:  Biochem Pharmacol       Date:  1989-01-01       Impact factor: 5.858

3.  Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein.

Authors:  M Petrini; D L Emerson; R M Galbraith
Journal:  Nature       Date:  1983 Nov 3-9       Impact factor: 49.962

4.  MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia.

Authors:  H Sato; H Preisler; R Day; A Raza; R Larson; G Browman; J Goldberg; R Vogler; H Grunwald; A Gottlieb
Journal:  Br J Haematol       Date:  1990-07       Impact factor: 6.998

5.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

6.  Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.

Authors:  E Friche; M K Danks; W T Beck
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

7.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.

Authors:  R F Ozols; R E Cunnion; R W Klecker; T C Hamilton; Y Ostchega; J E Parrillo; R C Young
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

8.  Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

Authors:  F Bessho; H Kinumaki; M Kobayashi; H Habu; K Nakamura; S Yokota; T Tsuruo; N Kobayashi
Journal:  Med Pediatr Oncol       Date:  1985

9.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.

Authors:  P H Wiernik; P L Banks; D C Case; Z A Arlin; P O Periman; M B Todd; P S Ritch; R E Enck; A B Weitberg
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.